WHO ICTRP trial
Effect of N acetylcysteine on pulmonary function in patients with scleroderma
IRCT2014012616367N1 · Iranian Registry of Clinical Trials (IRCT) · Not Recruiting
Key facts
| Trial ID | IRCT2014012616367N1 |
|---|---|
| Public title | Effect of N acetylcysteine on pulmonary function in patients with scleroderma |
| Scientific title | Determination of effect of N acetylcysteine on pulmonary function in patients with diffuse scleroderma |
| Primary sponsor | Vice chancellor for research, Shiraz University of Medical Sciences |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Not Recruiting |
| Study type | interventional |
| Phase | 2-3 |
| Countries | Iran (Islamic Republic of) |
| Conditions | lung involvement in scleroderma. Respiratory disorders in other diffuse connective tissue disorders (systemic sclerosis);Respiratory disorders in other diffuse connective tissue disorders (systemic sclerosis) |
| Interventions | Intervention 1: Intervention group: Tablets of Nacetylcysteine (NAC) are product of IRAN and 600mg. Therapy is with 1200 mg NAC daily that divided two times a day for six months. Intervention 2: Control group: Placebo will be given 2 times… |
| Registration date | Dec 4, 2014 |
| Target size | 24 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: